-
2
-
-
36148961146
-
The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substrates
-
Burk O and Schwab M (2007) The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substrates. Eur J Clin Pharmacol 63:1097-1098.
-
(2007)
Eur J Clin Pharmacol
, vol.63
, pp. 1097-1098
-
-
Burk, O.1
Schwab, M.2
-
3
-
-
33645864935
-
Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro
-
Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, and Thummel KE (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836-847.
-
(2006)
Drug Metab Dispos
, vol.34
, pp. 836-847
-
-
Dai, Y.1
Hebert, M.F.2
Isoherranen, N.3
Davis, C.L.4
Marsh, C.5
Shen, D.D.6
Thummel, K.E.7
-
4
-
-
34247371529
-
Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes
-
Dennison JB, Jones DR, Renbarger JL, and Hall SD (2007) Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 321:553-563.
-
(2007)
J Pharmacol Exp Ther
, vol.321
, pp. 553-563
-
-
Dennison, J.B.1
Jones, D.R.2
Renbarger, J.L.3
Hall, S.D.4
-
5
-
-
21044454884
-
Diagnosis and treatment of Alzheimer's disease
-
Desai AK and Grossberg GT (2005) Diagnosis and treatment of Alzheimer's disease. Neurology 64:S34-S39.
-
(2005)
Neurology
, vol.64
-
-
Desai, A.K.1
Grossberg, G.T.2
-
6
-
-
49449101906
-
Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease
-
Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, et al. (2008) Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease. Arch Neurol 65:1031-1038.
-
(2008)
Arch Neurol
, vol.65
, pp. 1031-1038
-
-
Fleisher, A.S.1
Raman, R.2
Siemers, E.R.3
Becerra, L.4
Clark, C.M.5
Dean, R.A.6
Farlow, M.R.7
Galvin, J.E.8
Peskind, E.R.9
Quinn, J.F.10
-
7
-
-
0028985574
-
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein
-
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, and Gillespie F (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523-527.
-
(1995)
Nature
, vol.373
, pp. 523-527
-
-
Games, D.1
Adams, D.2
Alessandrini, R.3
Barbour, R.4
Berthelette, P.5
Blackwell, C.6
Carr, T.7
Clemens, J.8
Donaldson, T.9
Gillespie, F.10
-
8
-
-
21544438539
-
Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor
-
Gitter B, Czilli D, Li W, Dieckman D, Bender M, Nissen J, Mabry T, Yin T, Boggs L, McClure D, et al. (2004) Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor. Neurobiol Aging 25 (Suppl 2):S571.
-
(2004)
Neurobiol Aging
, vol.25
, Issue.SUPPL. 2
-
-
Gitter, B.1
Czilli, D.2
Li, W.3
Dieckman, D.4
Bender, M.5
Nissen, J.6
Mabry, T.7
Yin, T.8
Boggs, L.9
McClure, D.10
-
9
-
-
21544470736
-
Reduction in Aβ(1- 40) and Aβ(1-42) in CSF and plasma in the beagle dog following acute oral dosing of the γ secretase inhibitor, LY450139
-
Hyslop P, May P, Audia J, Calligaro D, McMillian C, Garner C, Cramer J, Gitter B, Porter W, and Nissen J (2004) Reduction in Aβ(1- 40) and Aβ(1-42) in CSF and plasma in the beagle dog following acute oral dosing of the γ secretase inhibitor, LY450139. Neurobiol Aging 25 (Suppl 2):S147.
-
(2004)
Neurobiol Aging
, vol.25
, Issue.SUPPL. 2
-
-
Hyslop, P.1
May, P.2
Audia, J.3
Calligaro, D.4
McMillian, C.5
Garner, C.6
Cramer, J.7
Gitter, B.8
Porter, W.9
Nissen, J.10
-
10
-
-
40349111175
-
Therapeutic potential of γ-secretase inhibitors and modulators
-
Imbimbo BP (2008) Therapeutic potential of γ-secretase inhibitors and modulators. Curr Top Med Chem 8:54-61.
-
(2008)
Curr Top Med Chem
, vol.8
, pp. 54-61
-
-
Imbimbo, B.P.1
-
11
-
-
34249680308
-
Burden of illness among commercially insured patients with Alzheimer's disease
-
Joyce AT, Zhao Y, Bowman L, Flynn JA, Carter CT, and Ollendorf DA (2007) Burden of illness among commercially insured patients with Alzheimer's disease. Alzheimers Dement 3:204-210.
-
(2007)
Alzheimers Dement
, vol.3
, pp. 204-210
-
-
Joyce, A.T.1
Zhao, Y.2
Bowman, L.3
Flynn, J.A.4
Carter, C.T.5
Ollendorf, D.A.6
-
12
-
-
34548681861
-
Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam
-
Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, and Ensign D (2007) Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 82:410-426.
-
(2007)
Clin Pharmacol Ther
, vol.82
, pp. 410-426
-
-
Kharasch, E.D.1
Walker, A.2
Isoherranen, N.3
Hoffer, C.4
Sheffels, P.5
Thummel, K.6
Whittington, D.7
Ensign, D.8
-
13
-
-
0035071598
-
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
-
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics 27:383-391.
-
(2001)
Nature Genetics
, vol.27
, pp. 383-391
-
-
Kuehl, P.1
Zhang, J.2
Lin, Y.3
Lamba, J.4
Assem, M.5
Schuetz, J.6
Watkins, P.B.7
Daly, A.8
Wrighton, S.A.9
Hall, S.D.10
-
14
-
-
33751174340
-
Concentration-dependent modulation of amyloid-β in vivo and in vitro using the γ-secretase inhibitor, LY-450139
-
Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, Brown TM, Nolan CE, Richter KE, Finley JE, et al. (2006) Concentration-dependent modulation of amyloid-β in vivo and in vitro using the γ-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 319: 924-933.
-
(2006)
J Pharmacol Exp Ther
, vol.319
, pp. 924-933
-
-
Lanz, T.A.1
Karmilowicz, M.J.2
Wood, K.M.3
Pozdnyakov, N.4
Du, P.5
Piotrowski, M.A.6
Brown, T.M.7
Nolan, C.E.8
Richter, K.E.9
Finley, J.E.10
-
15
-
-
21544457270
-
Multi-compartmental pharmacodynamic assessment of the functional γ-secretase inhibitor LY450139 in PDAPP transgenic and nontransgenic mice
-
(Suppl 2)
-
May P, Yang Z, Li W-Y, Hyslop P, Siemers E, and Boggs L (2004) Multi-compartmental pharmacodynamic assessment of the functional γ-secretase inhibitor LY450139 in PDAPP transgenic and nontransgenic mice. Neurobiol Aging 25 (Suppl 2):S65.
-
(2004)
Neurobiol Aging
, vol.25
-
-
May, P.1
Yang, Z.2
Li, W.-Y.3
Hyslop, P.4
Siemers, E.5
Boggs, L.6
-
16
-
-
21544432780
-
Reduced β-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months
-
Ness D, Boggs L, Hepburn DL, Gitter B, Long G, May P, Piroozi K, Schafer K, and Yang Z (2004) Reduced β-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months. Neurobiol Aging 25 (Suppl 2):S238-S239.
-
(2004)
Neurobiol Aging
, vol.25
, Issue.SUPPL. 2
-
-
Ness, D.1
Boggs, L.2
Hepburn, D.L.3
Gitter, B.4
Long, G.5
May, P.6
Piroozi, K.7
Schafer, K.8
Yang, Z.9
-
17
-
-
40349100482
-
Recent progress in the medicinal chemistry of γ-secretase inhibitors
-
Olson RE and Albright CF (2008) Recent progress in the medicinal chemistry of γ-secretase inhibitors. Curr Top Med Chem 8:17-33.
-
(2008)
Curr Top Med Chem
, vol.8
, pp. 17-33
-
-
Olson, R.E.1
Albright, C.F.2
-
18
-
-
34748899687
-
Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes
-
Perrett HF, Barter ZE, Jones BC, Yamazaki H, Tucker GT, and Rostami-Hodjegan A (2007) Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. Drug Metab Dispos 35:1733-1736.
-
(2007)
Drug Metab Dispos
, vol.35
, pp. 1733-1736
-
-
Perrett, H.F.1
Barter, Z.E.2
Jones, B.C.3
Yamazaki, H.4
Tucker, G.T.5
Rostami-Hodjegan, A.6
-
19
-
-
0034861814
-
Prevalence, costs, and treatment of Alzheimer's disease and related dementia: A managed care perspective
-
Rice DP, Fillit HM, Max W, Knopman DS, Lloyd JR, and Duttagupta S (2001) Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am J Manag Care 7:809-818.
-
(2001)
Am J Manag Care
, vol.7
, pp. 809-818
-
-
Rice, D.P.1
Fillit, H.M.2
Max, W.3
Knopman, D.S.4
Lloyd, J.R.5
Duttagupta, S.6
-
20
-
-
0035066332
-
Alzheimer's disease: Genes, proteins, and therapy
-
Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
-
(2001)
Physiol Rev
, vol.81
, pp. 741-766
-
-
Selkoe, D.J.1
-
21
-
-
0028237729
-
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
-
Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
-
(1994)
J Pharmacol Exp Ther
, vol.270
, pp. 414-423
-
-
Shimada, T.1
Yamazaki, H.2
Mimura, M.3
Inui, Y.4
Guengerich, F.P.5
-
22
-
-
21544458621
-
Safety, tolerability, and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers
-
Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, and May PC (2005) Safety, tolerability, and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers. Clin Neuropharmacol 28:126-132.
-
(2005)
Clin Neuropharmacol
, vol.28
, pp. 126-132
-
-
Siemers, E.1
Skinner, M.2
Dean, R.A.3
Gonzales, C.4
Satterwhite, J.5
Farlow, M.6
Ness, D.7
May, P.C.8
-
23
-
-
37349072443
-
Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-β after inhibition of γ-secretase
-
Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, and May PC (2007) Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-β after inhibition of γ-secretase. Clin Neuropharmacol 30:317-325.
-
(2007)
Clin Neuropharmacol
, vol.30
, pp. 317-325
-
-
Siemers, E.R.1
Dean, R.A.2
Friedrich, S.3
Ferguson-Sells, L.4
Gonzales, C.5
Farlow, M.R.6
May, P.C.7
-
24
-
-
33645013015
-
Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease
-
Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, et al. (2006) Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66:602-604.
-
(2006)
Neurology
, vol.66
, pp. 602-604
-
-
Siemers, E.R.1
Quinn, J.F.2
Kaye, J.3
Farlow, M.R.4
Porsteinsson, A.5
Tariot, P.6
Zoulnouni, P.7
Galvin, J.E.8
Holtzman, D.M.9
Knopman, D.S.10
-
25
-
-
0242332169
-
Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
-
Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, and Daly AK (2003) Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233-1235.
-
(2003)
Transplantation
, vol.76
, pp. 1233-1235
-
-
Thervet, E.1
Anglicheau, D.2
King, B.3
Schlageter, M.H.4
Cassinat, B.5
Beaune, P.6
Legendre, C.7
Daly, A.K.8
-
26
-
-
19144368324
-
Cytochrome P450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance
-
Totah RA and Rettie AE (2005) Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77:341-352.
-
(2005)
Clin Pharmacol Ther
, vol.77
, pp. 341-352
-
-
Totah, R.A.1
Rettie, A.E.2
-
27
-
-
3543042787
-
Genetic variability in CYP3A5 and its possible consequences
-
Xie HG, Wood AJ, Kim RB, Stein CM, and Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.
-
(2004)
Pharmacogenomics
, vol.5
, pp. 243-272
-
-
Xie, H.G.1
Wood, A.J.2
Kim, R.B.3
Stein, C.M.4
Wilkinson, G.R.5
|